A5020698248- Gastric Cancer Management and Outcomes
- Esophageal Cancer Research and Treatment
- DNA Repair Mechanisms
- Cancer, Hypoxia, and Metabolism
- PARP inhibition in cancer therapy
- Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Cancer-related Molecular Pathways
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Mitochondrial Function and Pathology
- Gastrointestinal Tumor Research and Treatment
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Radiation Therapy and Dosimetry
- Helicobacter pylori-related gastroenterology studies
- Metastasis and carcinoma case studies
- Blood Pressure and Hypertension Studies
- Economic and Financial Impacts of Cancer
- Cancer therapeutics and mechanisms
- Spinal Hematomas and Complications
- Sarcoma Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Breast Cancer Treatment Studies
- Cancer Risks and Factors
Merck & Co., Inc., Rahway, NJ, USA (United States)
2021-2025
Bayer (United States)
2019-2020
Brooklyn Hospital Center
2014-2016
Kings County Hospital Center
2007
SUNY Downstate Health Sciences University
2007
The phase III POLO study demonstrated significant progression-free survival (PFS) benefit for active olaparib maintenance therapy versus placebo patients with metastatic pancreatic adenocarcinoma and a germline BRCA mutation. Here, we report the final analysis of overall (OS) other secondary end points.
Despite curative-intent treatment, most patients with locally advanced esophageal cancer will experience disease recurrence or locoregional progression, highlighting the need for new therapies. Current guidelines recommend definitive chemoradiotherapy in ineligible surgical resection, but survival outcomes are poor. Pembrolizumab is well tolerated and provides promising antitumor activity previously treated, advanced, unresectable esophageal/esophagogastric junction cancer. Combining...
4045 Background: At the protocol-specified interim analysis of KEYNOTE-859 study (NCT03675737), first-line pembro + chemo significantly improved OS (HR, 0.78; 95% CI, 0.70-0.87; P<0.0001), PFS 0.76; 0.67-0.85; and ORR (51.3% vs 42.0%; P=0.00009) placebo (pbo) in patients (pts) with HER2-negative G/GEJ cancer. We report results after an additional 11 months follow-up. Methods: Pts previously untreated locally advanced or metastatic cancer, measurable disease per RECIST v1.1, ECOG PS 0 1,...
412 Background: Drug development in esophageal cancer is rapidly evolving, and identifying surrogates for patient outcomes to accelerate clinical drug remains an important unmet medical need. Although early endpoints such as EFS, disease free survival (DFS) are proven be valid overall (OS) (Ajani JA et al. 2022), gastric (Oba K 2013; Wainberg ZA 2023), gastroesophageal junction tumors (Ronellenfitsch U. 2013) after resection, there no surrogacy data evaluating patients who underwent...
Results of the global, randomized, phase 3 KEYNOTE-859 study (N = 1579) showed that first-line pembrolizumab plus chemotherapy produced a statistically significant and clinically meaningful improvement in overall survival (OS) with manageable toxicity versus placebo patients locally advanced or metastatic human epidermal growth factor receptor 2 (HER2)–negative gastric gastroesophageal junction cancer. This subgroup analysis was conducted to investigate outcomes enrolled mainland China....
4014 Background: In the ITT population of KEYNOTE-859 study HER2-negative, advanced G/GEJ cancer (NCT03675737), pembrolizumab (pembro) + chemotherapy (chemo) significantly improved OS (HR 0.78, 95% CI 0.70-0.87; P < 0.0001), PFS 0.76, 0.67-0.85; and ORR (51.3% vs 42.0%; = 0.00009) placebo chemo at protocol-specified interim analysis. The safety profile pembro was as expected. We present efficacy outcomes PD-L1 combined positive score (CPS) ≥1 CPS ≥10 populations. Methods: Eligible pts...
3007 Background: The ATR kinase is a key regulator of the DNA damage response (DDR) machinery, activated by and replication stress. BAY 1895344 novel, potent, selective inhibitor with anti-tumor activity in preclinical models DDR defects. Methods: Pts advanced metastatic solid tumors resistant or refractory to standard treatment, without defects, received BID, 3 days (d) on/4 d off continuously 3-weekly cycles. Results: As December 20, 2018, 18 pts colorectal (4), breast (3), prostate (2),...
Our objective was to assess the gender-related effects of alcohol consumption on blood pressure (BP) in a representative sample adult US population.We examined data from National Health and Nutrition Examination Survey 1999-2000. The various risk factors for hypertension BP were with analysis covariance statistics.Of 5448 adults over 20 years age, 2650 (48.7%) reported intake one or more drinks per day past year. In this population, mean +/- SEM age 46.9 0.34 years, body mass index 24.8...
Prostate cancer is the second most common cause of death in men United States. The sites metastasis include bone, lymph nodes, lung, liver, pleura, and adrenal glands, whereas metastatic prostate involving gastrointestinal tract has been rarely reported. A 64-year-old African-American man with a history presented anemia. He reported passing dark colored stools but denied hematemesis or hematochezia. Colonoscopy revealed circumferential nodularity, histology demonstrated carcinoma prostate....
345 Background: First-line (1L) treatment of GEJC and EAC is similar to that for gastric adenocarcinomas, based on evidence from 2 large phase 3 esophageal cancer trials. The KEYNOTE-590 trial (NCT03189719) showed 1L pembro + chemo significantly improved OS PFS in pts with cancer. KEYNOTE-859 (NCT03675737) OS, PFS, ORR HER2-negative or GEJC. This post hoc, exploratory analysis was conducted examine the efficacy subgroups GEJ subgroup KEYNOTE-859. Methods: Pts untreated advanced Siewert type...
e23273 Background: Definitive chemoradiotherapy (dCRT) is the recommended treatment for patients with early-stage EC/GEJC not eligible surgery. There have been improvements esophageal cancer, but overall 5-year survival rates remain low at approximately 20%. This study examined patient characteristics, current patterns and outcomes dCRT regimens in US community oncology setting. Methods: was a retrospective observational cohort using structured unstructured electronic health records data of...
It is well-known that malignancies, particularly pancreatic and brain cancers, often present as venous thromboembolism. However, stroke angina attributable to arterial occlusion are relatively common presentations well. We reporting a patient, with treatment-naïve hepatitis C multiple liver nodules, was admitted for deep vein thrombosis (DVT) pulmonary embolism (PE). Subsequently, she developed an ascending paralysis due spinal cord infarct (SCI) despite adequate anticoagulation. She also...
<div>Abstract<p>Targeting the ataxia telangiectasia and RAD3-related (ATR) enzyme represents a promising anticancer strategy for tumors with DNA damage response (DDR) defects replication stress, including inactivation of mutated (ATM) signaling. We report dose-escalation portion phase I first-in-human trial oral ATR inhibitor BAY 1895344 intermittently dosed 5 to 80 mg twice daily in 21 patients advanced solid tumors. The MTD was 40 3 days on/4 off. Most common adverse events...
e12057 Background: Increased mammographic density (MD) has been shown to be an independent risk factor for breast cancer. Women with dense as determined by a diagnostic mammogram are at 1.8 6 times greater of developing cancer than those the same age without increased density. We investigated whether there is any association between MD and estrogen receptor ( ER ) or progesterone PR status invasive ductal carcinoma in situ (DCIS) modified body mass index (BMI), menopausal race. Methods:...
<p>Supplementary Data</p>
<div>Abstract<p>Targeting the ataxia telangiectasia and RAD3-related (ATR) enzyme represents a promising anticancer strategy for tumors with DNA damage response (DDR) defects replication stress, including inactivation of mutated (ATM) signaling. We report dose-escalation portion phase I first-in-human trial oral ATR inhibitor BAY 1895344 intermittently dosed 5 to 80 mg twice daily in 21 patients advanced solid tumors. The MTD was 40 3 days on/4 off. Most common adverse events...
<p>Supplementary Data</p>
e11075 Background: Treated BC DM may remain stable for many months. Primary or recurrent LRM cause significant morbidity. In patients with and LRM, the are usually major objects of therapy. Methods: Charts 372 Kings County Medical Center Breast Clinic locally advanced presenting between 1996 2009 were reviewed. Of 80 inoperable only symptoms 20 due to prolonged periods. Results: these duration was 3-87 months; median 16, mean 22 included 7 inflamed breast masses, 5 ulcerations (3...